Flputnam Investment Management Co. Has $635,000 Stake in Becton, Dickinson and Company $BDX

Flputnam Investment Management Co. reduced its holdings in Becton, Dickinson and Company (NYSE:BDX) by 6.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,773 shares of the medical instruments supplier’s stock after selling 199 shares during the quarter. Flputnam Investment Management Co.’s holdings in Becton, Dickinson and Company were worth $635,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Quarry LP grew its position in shares of Becton, Dickinson and Company by 3,132.6% in the first quarter. Quarry LP now owns 1,390 shares of the medical instruments supplier’s stock valued at $318,000 after purchasing an additional 1,347 shares during the last quarter. Saudi Central Bank acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at about $26,000. Connecticut Wealth Management LLC grew its position in shares of Becton, Dickinson and Company by 1.9% in the first quarter. Connecticut Wealth Management LLC now owns 3,608 shares of the medical instruments supplier’s stock valued at $826,000 after purchasing an additional 67 shares during the last quarter. Baird Financial Group Inc. grew its position in shares of Becton, Dickinson and Company by 15.9% in the first quarter. Baird Financial Group Inc. now owns 103,729 shares of the medical instruments supplier’s stock valued at $23,760,000 after purchasing an additional 14,266 shares during the last quarter. Finally, Panagora Asset Management Inc. grew its position in shares of Becton, Dickinson and Company by 8.2% in the first quarter. Panagora Asset Management Inc. now owns 232,007 shares of the medical instruments supplier’s stock valued at $53,144,000 after purchasing an additional 17,589 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 863 shares of the firm’s stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $192.30, for a total transaction of $165,954.90. Following the completion of the transaction, the director owned 23,143 shares in the company, valued at $4,450,398.90. This trade represents a 3.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. This represents a 19.52% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is owned by company insiders.

Becton, Dickinson and Company Stock Down 2.5%

BDX stock opened at $188.11 on Wednesday. The company has a market cap of $53.92 billion, a PE ratio of 33.83, a price-to-earnings-growth ratio of 1.44 and a beta of 0.27. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The business’s 50-day simple moving average is $183.86 and its 200 day simple moving average is $193.57.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.28. The firm had revenue of $5.51 billion during the quarter, compared to analysts’ expectations of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter last year, the company earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be paid a dividend of $1.04 per share. The ex-dividend date is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 74.82%.

Analysts Set New Price Targets

BDX has been the topic of several research analyst reports. Wells Fargo & Company raised their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Morgan Stanley lifted their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Piper Sandler reissued a “neutral” rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Finally, Barclays decreased their target price on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a research report on Tuesday, June 3rd. Four research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $211.44.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.